Market Overview

Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend

Share:
Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend

NeuroMetrix Inc (NASDAQ: NURO) is a commercial-stage health care technology company with two products on the market: Quell, an OTC wearable device relying on neurostimulation technology for chronic pain relief; and DPNCheck, a point-of-care diabetic peripheral neuropathy test.

With $17.1 million in sales in 2017, NeuroMetrix’s market capitalization of approximately $5 million appears low, according to H.C. Wainwright.

The Analyst

Analyst Andrew Fein initiated coverage of NeuroMetrix with a Buy rating and $5 price target.

The Thesis

NeuroMetrix’s stock seems underappreciated, and any positivity from the company could lend upside to its share price, Fein said in the Wednesday initiation note. (See the analyst's track record here.) 

Quell 2.0, which was launched in the U.S. in September, could boost market adoption given that the new device is smarter, half the size of the original Quell device and runs on an improved app, the analyst said. Quell 2.0 is expected to be launched outside the U.S. in 2019 and beyond, he said. 

NeuroMetrix is selling Quell 2.0 to the highest-profit margin channels of e-commerce, and the company’s gross margins could expand over the next couple of years, Fein said. 

A regulatory environment that seeks to reduce new addictions through opioid use and increase the use of alternative pain management bodes well for Quell's adoption, in H.C. Wainwright's view. 

NeuroMetrix’s commercial downside and financial risks “are limited by a number of partnerships,” Fein said. 

Price Action

NeuroMetrix shares were trading up 6.12 percent to 72 cents at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

NeuroMetrix Reports Q4 and Full Year 2017 Financial Results

Latest Ratings for NURO

DateFirmActionFromTo
Jun 2016Initiates Coverage onBuy
Apr 2012Initiates Coverage onBuy

View More Analyst Ratings for NURO
View the Latest Analyst Ratings

Posted-In: Andrew Fein H.C. WainwrightAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga

 

Related Articles (NURO)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SKXMaintains44.0
HYMaintains66.0
MSFTMaintains160.0
SKXUpgrades
WLTWMaintains208.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

6 Valuable Pipeline Drugs With Upcoming Catalysts

Estate Planning: What Are Per Capita And Per Stirpes Beneficiary Designations?